1
|
Shahzadi A, Yunusoglu O, Karabulut E, Sonmez H, Yazici Z. Influence of Selective Dopamine Agonist Ropinirole on Conditioned Place Preference and Somatic Signs of Morphine Withdrawal in Rats. Front Behav Neurosci 2022; 16:855241. [PMID: 35733518 PMCID: PMC9207507 DOI: 10.3389/fnbeh.2022.855241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Accepted: 04/04/2022] [Indexed: 11/13/2022] Open
Abstract
The underlying mechanism of dependence and rewarding effects of morphine is imperative to understand. The primary aim of this study was to investigate whether ropinirole D2/3 agonist affects the rewarding and reinforcing properties of morphine-induced conditioned place preference (CPP) and withdrawal syndromes in rats. On day one, the animals were randomly divided to conduct the pre-test. The morphine (10 mg/kg, i.p.) and/or saline was administered on alternate days in an 8-day CPP session. On day 10, 15 min prior to the post-conditioning test (expression), a single dose of ropinirole (1, 2, and 5 mg/kg, i.p.) was given to rats. In extinction session, ropinirole was injected daily, and CPP was extinguished by repeated testing, with intervals of 3 days. Finally, reinstatement was assessed by administering ropinirole (1, 2, and 5 mg/kg) 15 min before the morphine injection. Morphine dependence was developed by administering increasing doses of morphine (10–50 mg/kg, i.p.). To assess withdrawal symptoms, ropinirole (1, 2, and 5 mg/kg) was injected 15 min before naloxone (2 mg/kg, s.c.) administration. The present study confirms that ropinirole attenuates expression and reinstatement of CPP, while it precipitates the extinction of morphine-induced CPP. Naloxone-precipitated morphine withdrawal symptoms, including wet dog shakes and weight loss, were attenuated although jumping was increased by a single ropinirole injection. Thus, ropinirole was influential in attenuating expression, reducing drug seeking and weakening reinstatement via the dopaminergic system. These findings show that ropinirole might affect neuro-adaptive changes related to dependence.
Collapse
Affiliation(s)
- Andleeb Shahzadi
- Department of Medical Pharmacology, Faculty of Medicine-Cerrahpasa, Istanbul University-Cerrahpasa, Istanbul, Turkey
- *Correspondence: Andleeb Shahzadi,
| | - Oruc Yunusoglu
- Department of Medical Pharmacology, Faculty of Medicine-Cerrahpasa, Istanbul University-Cerrahpasa, Istanbul, Turkey
- Department of Medical Pharmacology, Faculty of Medicine, Bolu Abant Izzet Baysal University, Bolu, Turkey
| | - Enes Karabulut
- Department of Medical Pharmacology, Faculty of Medicine-Cerrahpasa, Istanbul University-Cerrahpasa, Istanbul, Turkey
- Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey
| | - Haktan Sonmez
- Department of Medical Pharmacology, Faculty of Medicine-Cerrahpasa, Istanbul University-Cerrahpasa, Istanbul, Turkey
| | - Zeliha Yazici
- Department of Medical Pharmacology, Faculty of Medicine-Cerrahpasa, Istanbul University-Cerrahpasa, Istanbul, Turkey
- Department of Medical Pharmacology, Faculty of Medicine, Biruni University, Istanbul, Turkey
- Zeliha Yazici, ;
| |
Collapse
|
2
|
The Role of Dopamine D3 Receptors in Tobacco Use Disorder: A Synthesis of the Preclinical and Clinical Literature. Curr Top Behav Neurosci 2022; 60:203-228. [PMID: 36173599 DOI: 10.1007/7854_2022_392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Tobacco smoking is a significant cause of preventable morbidity and mortality globally. Current pharmacological approaches to treat tobacco use disorder (TUD) are only partly effective and novel approaches are needed. Dopamine has a well-established role in substance use disorders, including TUD, and there has been a long-standing interest in developing agents that target the dopaminergic system to treat substance use disorders. Dopamine has 5 receptor subtypes (DRD1 to DRD5). Given the localization and safety profile of the dopamine receptor D3 (DRD3), it is of therapeutic potential for TUD. In this chapter, the preclinical and clinical literature investigating the role of DRD3 in processes relevant to TUD will be reviewed, including in nicotine reinforcement, drug reinstatement, conditioned stimuli and cue-reactivity, executive function, and withdrawal. Similarities and differences in findings from the animal and human work will be synthesized and findings will be discussed in relation to the therapeutic potential of targeting DRD3 in TUD.
Collapse
|
3
|
Nishitani N, Ohmura Y, Kobayashi K, Murashita T, Yoshida T, Yoshioka M. Serotonin neurons in the median raphe nucleus bidirectionally regulate somatic signs of nicotine withdrawal in mice. Biochem Biophys Res Commun 2021; 562:62-68. [PMID: 34038754 DOI: 10.1016/j.bbrc.2021.05.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Accepted: 05/16/2021] [Indexed: 10/21/2022]
Abstract
In chronic smokers, nicotine withdrawal symptoms during tobacco cessation can lead to smoking relapse. In rodent models, chronic exposure to nicotine elicited physical dependence, whereas acute antagonism of nicotinic acetylcholine receptors (nAChRs) immediately precipitated withdrawal symptoms. Although the central serotonergic system plays an important role in nicotine withdrawal, the exact serotonergic raphe nuclei regulating these symptoms remain unknown. We used transgenic mice expressing archaerhodopsinTP009 or channelrhodopsin-2[C128S] exclusively in the central serotonergic neurons to selectively manipulate serotonergic neurons in each raphe nucleus. Nicotine withdrawal symptoms were precipitated by an acute injection of mecamylamine, a nonspecific nAChR antagonist, following chronic nicotine consumption. Somatic signs were used as measures of nicotine withdrawal symptoms. Acute mecamylamine administration significantly increased ptosis occurrence in nicotine-drinking mice compared with that in control-drinking mice. Optogenetic inhibition of the serotonergic neurons in the median raphe nucleus (MRN), but not of those in the dorsal raphe nucleus (DRN), mimicked the symptoms observed during mecamylamine-precipitated nicotine withdrawal even in nicotine-naïve mice following the administration of acute mecamylamine injection. Optogenetic activation of the serotonergic neurons in the MRN nearly abolished the occurrence of ptosis in nicotine-drinking mice. The serotonergic neurons in the MRN, but not those in the DRN, are necessary for the occurrence of somatic signs, a nicotine withdrawal symptom, and the activation of these neurons may act as a potential therapeutic strategy for preventing the somatic manifestations of nicotine withdrawal.
Collapse
Affiliation(s)
- Naoya Nishitani
- Department of Neuropharmacology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15 W7 Kita-ku, Sapporo, 060-8638, Japan
| | - Yu Ohmura
- Department of Neuropharmacology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15 W7 Kita-ku, Sapporo, 060-8638, Japan.
| | - Keita Kobayashi
- Hokkaido University School of Medicine, N15 W7 Kita-ku, Sapporo, 060-8638, Japan
| | - Taichi Murashita
- Hokkaido University School of Medicine, N15 W7 Kita-ku, Sapporo, 060-8638, Japan
| | - Takayuki Yoshida
- Department of Neuropharmacology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15 W7 Kita-ku, Sapporo, 060-8638, Japan
| | - Mitsuhiro Yoshioka
- Department of Neuropharmacology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15 W7 Kita-ku, Sapporo, 060-8638, Japan
| |
Collapse
|
4
|
Tsutsui-Kimura I, Ohmura Y, Yoshida T, Yoshioka M. Milnacipran affects mouse impulsive, aggressive, and depressive-like behaviors in a distinct dose-dependent manner. J Pharmacol Sci 2017; 134:181-189. [PMID: 28694090 DOI: 10.1016/j.jphs.2017.06.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2017] [Revised: 06/12/2017] [Accepted: 06/14/2017] [Indexed: 12/12/2022] Open
Abstract
Serotonin/noradrenaline reuptake inhibitors (SNRIs) are widely used for the treatment for major depressive disorder, but these drugs induce several side effects including increased aggression and impulsivity, which are risk factors for substance abuse, criminal involvement, and suicide. To address this issue, milnacipran (0, 3, 10, or 30 mg/kg), an SNRI and antidepressant, was intraperitoneally administered to mice prior to the 3-choice serial reaction time task, resident-intruder test, and forced swimming test to measure impulsive, aggressive, and depressive-like behaviors, respectively. A milnacipran dose of 10 mg/kg suppressed all behaviors, which was accompanied by increased dopamine and serotonin levels in the medial prefrontal cortex (mPFC) but not in the nucleus accumbens (NAc). Although the most effective dose for depressive-like behavior was 30 mg/kg, the highest dose increased aggressive behavior and unaffected impulsive behavior. Increased dopamine levels in the NAc could be responsible for the effects. In addition, the mice basal impulsivity was negatively correlated with the latency to the first agonistic behavior. Thus, the optimal dose range of milnacipran is narrower than previously thought. Finding drugs that increase serotonin and dopamine levels in the mPFC without affecting dopamine levels in the NAc is a potential strategy for developing novel antidepressants.
Collapse
Affiliation(s)
- Iku Tsutsui-Kimura
- Department of Neuropsychiatry, Keio University, School of Medicine, Tokyo 160-8582, Japan; Japan Society for the Promotion of Science, Japan; Department of Neuropharmacology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.
| | - Yu Ohmura
- Department of Neuropharmacology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.
| | - Takayuki Yoshida
- Department of Neuropharmacology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan
| | - Mitsuhiro Yoshioka
- Department of Neuropharmacology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan
| |
Collapse
|
5
|
Ohmura Y, Sasamori H, Tsutsui-Kimura I, Izumi T, Yoshida T, Yoshioka M. Varenicline provokes impulsive action by stimulating α4β2 nicotinic acetylcholine receptors in the infralimbic cortex in a nicotine exposure status-dependent manner. Pharmacol Biochem Behav 2017; 154:1-10. [DOI: 10.1016/j.pbb.2017.01.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2016] [Revised: 12/04/2016] [Accepted: 01/09/2017] [Indexed: 10/20/2022]
|
6
|
Yang XQ, Glizer D, Vo A, Seergobin KN, MacDonald PA. Pramipexole Increases Go Timeouts but Not No-go Errors in Healthy Volunteers. Front Hum Neurosci 2016; 10:523. [PMID: 27803657 PMCID: PMC5067488 DOI: 10.3389/fnhum.2016.00523] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Accepted: 10/03/2016] [Indexed: 12/03/2022] Open
Abstract
Parkinson's disease (PD) is characterized by motor symptoms, such as resting tremor, bradykinesia and rigidity, but also features non-motor complications. PD patients taking dopaminergic therapy, such as levodopa but especially dopamine agonists (DAs), evidence an increase in impulse control disorders (ICDs), suggesting a link between dopaminergic therapy and impulsive pursuit of pleasurable activities. However, impulsivity is a multifaceted construct. Motor impulsivity refers to the inability to overcome automatic responses or cancel pre-potent responses. Previous research has suggested that PD patients, on dopaminergic medications, have decreased motor impulsivity. Whether effects on impulsivity are main effects of dopaminergic therapies or are specific to PD is unclear. Using a Go No-go task, we investigated the effect of a single dose of the DA pramipexole on motor impulsivity in healthy participants. The Go No-go task consisted of Go trials, for which keystroke responses were made as quickly as possible, and lesser frequency No-go trials, on which motor responses were to be inhibited. We hypothesized that pramipexole would decrease motor impulsivity. This would manifest as: (a) fewer No-go errors (i.e., fewer responses on trials in which a response ought to have been inhibited); and (b) more timed-out Go trials (i.e., more trials on which the deadline elapsed before a decision to make a keystroke occurred). Healthy volunteers were treated with either 0.5 mg of pramipexole or a standard placebo (randomly determined). During the 2-h wait period, they completed demographic, cognitive, physiological and affective measures. The pramipexole group had significantly more Go timeouts (p < 0.05) compared to the placebo group though they did not differ in percent of No-go errors. In contrast to its effect on pursuit of pleasurable activities, pramipexole did not increase motor impulsivity. In fact, in line with findings in PD and addiction, dopaminergic therapy might increase motor impulse control. In these patient groups, by enhancing function of the dorsal striatum (DS) of the basal ganglia in contrast to its effect on impulsive pursuit of pleasurable activities. These findings have implications for use and effects of pramipexole in PD as well as in other conditions (e.g., restless leg, dystonia, depression, addiction-related problems).
Collapse
Affiliation(s)
- Xue Qing Yang
- MacDonald Lab, Brain and Mind Institute, University of Western OntarioLondon, ON, Canada
| | - Daniel Glizer
- MacDonald Lab, Brain and Mind Institute, University of Western OntarioLondon, ON, Canada
| | - Andrew Vo
- MacDonald Lab, Brain and Mind Institute, University of Western OntarioLondon, ON, Canada
| | - Ken N. Seergobin
- MacDonald Lab, Brain and Mind Institute, University of Western OntarioLondon, ON, Canada
| | - Penny A. MacDonald
- MacDonald Lab, Brain and Mind Institute, University of Western OntarioLondon, ON, Canada
- Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, University of Western OntarioLondon, ON, Canada
| |
Collapse
|
7
|
Morales-Rosado JA, Cousin MA, Ebbert JO, Klee EW. A Critical Review of Repurposing Apomorphine for Smoking Cessation. Assay Drug Dev Technol 2015; 13:612-22. [DOI: 10.1089/adt.2015.680] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - Margot A. Cousin
- Mayo Addiction Research Center, Mayo Clinic, Rochester, Minnesota
| | - Jon O. Ebbert
- Mayo Addiction Research Center, Mayo Clinic, Rochester, Minnesota
| | - Eric W. Klee
- Mayo Addiction Research Center, Mayo Clinic, Rochester, Minnesota
| |
Collapse
|
8
|
Effects of oxytocin on nicotine withdrawal in rats. Pharmacol Biochem Behav 2014; 116:84-9. [DOI: 10.1016/j.pbb.2013.11.002] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/15/2013] [Revised: 10/31/2013] [Accepted: 11/07/2013] [Indexed: 12/16/2022]
|
9
|
Jensen K, Afroze S, Ueno Y, Rahal K, Frenzel A, Sterling M, Guerrier M, Nizamutdinov D, Dostal DE, Meng F, Glaser SS. Chronic nicotine exposure stimulates biliary growth and fibrosis in normal rats. Dig Liver Dis 2013; 45:754-61. [PMID: 23587498 PMCID: PMC3800482 DOI: 10.1016/j.dld.2013.02.023] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2012] [Revised: 02/05/2013] [Accepted: 02/27/2013] [Indexed: 12/11/2022]
Abstract
BACKGROUND Epidemiological studies have indicated smoking to be a risk factor for the progression of liver diseases. Nicotine is the chief addictive substance in cigarette smoke and has powerful biological properties throughout the body. Nicotine has been implicated in a number of disease processes, including increased cell proliferation and fibrosis in several organ systems. AIMS The aim of this study was to evaluate the effects of chronic administration of nicotine on biliary proliferation and fibrosis in normal rats. METHODS In vivo, rats were treated with nicotine by osmotic minipumps for two weeks. Proliferation, α7-nicotinic receptor and profibrotic expression were evaluated in liver tissue, cholangiocytes and a polarized cholangiocyte cell line (normal rat intrahepatic cholangiocyte). Nicotine-dependent activation of the Ca(2+)/IP3/ERK 1/2 intracellular signalling pathway was also evaluated in normal rat intrahepatic cholangiocyte. RESULTS Cholangiocytes express α7-nicotinic receptor. Chronic administration of nicotine to normal rats stimulated biliary proliferation and profibrotic gene and protein expression such as alpha-smooth muscle actin and fibronectin 1. Activation of α7-nicotinic receptor stimulated Ca(2+)/ERK1/2-dependent cholangiocyte proliferation. CONCLUSION Chronic exposure to nicotine contributes to biliary fibrosis by activation of cholangiocyte proliferation and expression of profibrotic genes. Modulation of α7-nicotinic receptor signalling axis may be useful for the management of biliary proliferation and fibrosis during cholangiopathies.
Collapse
Affiliation(s)
- Kendal Jensen
- Scott & White Healthcare - Digestive Disease Research Center, Temple, Texas USA
| | - Syeda Afroze
- Scott & White Healthcare - Digestive Disease Research Center, Temple, Texas USA
| | - Yoshiyuki Ueno
- Department of Gastroenterology, Yamagata University Faculty of Medicine, Yamagata, Japan
| | - Kinan Rahal
- Texas A&M Health Science Center College of Medicine and Scott and White Healthcare Department of Internal Medicine, Division of Gastroenterology, Temple, Texas USA
| | - Amber Frenzel
- Undergraduate Research Program, Texas Bioscience Institute-Temple College, Temple, Texas USA
| | - Melanie Sterling
- Undergraduate Research Program, Texas Bioscience Institute-Temple College, Temple, Texas USA
| | - Micheleine Guerrier
- Scott & White Healthcare - Digestive Disease Research Center, Temple, Texas USA
| | - Damir Nizamutdinov
- Central Texas Veterans Health Care System, Temple, Texas USA
- Texas A&M Health Science Center College of Medicine and Scott and White Healthcare Department of Internal Medicine, Division of Molecular Cardiology, Temple, Texas USA
| | - David E. Dostal
- Central Texas Veterans Health Care System, Temple, Texas USA
- Texas A&M Health Science Center College of Medicine and Scott and White Healthcare Department of Internal Medicine, Division of Molecular Cardiology, Temple, Texas USA
| | - Fanyin Meng
- Central Texas Veterans Health Care System, Temple, Texas USA
- Scott & White Healthcare - Digestive Disease Research Center, Temple, Texas USA
- Texas A&M Health Science Center College of Medicine and Scott and White Healthcare Department of Internal Medicine, Division of Gastroenterology, Temple, Texas USA
| | - Shannon S. Glaser
- Central Texas Veterans Health Care System, Temple, Texas USA
- Scott & White Healthcare - Digestive Disease Research Center, Temple, Texas USA
- Texas A&M Health Science Center College of Medicine and Scott and White Healthcare Department of Internal Medicine, Division of Gastroenterology, Temple, Texas USA
| |
Collapse
|
10
|
Zugno AI, Fraga DB, De Luca RD, Ghedim FV, Deroza PF, Cipriano AL, Oliveira MB, Heylmann ASA, Budni J, Souza RP, Quevedo J. Chronic exposure to cigarette smoke during gestation results in altered cholinesterase enzyme activity and behavioral deficits in adult rat offspring: potential relevance to schizophrenia. J Psychiatr Res 2013; 47:740-6. [PMID: 23472836 DOI: 10.1016/j.jpsychires.2013.02.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2012] [Revised: 02/06/2013] [Accepted: 02/07/2013] [Indexed: 01/18/2023]
Abstract
Prenatal cigarette smoke exposure (PCSE) has been associated with physiological and developmental changes that may be related to an increased risk for childhood and adult neuropsychiatric diseases. The present study investigated locomotor activity and cholinesterase enzyme activity in rats, following PCSE and/or ketamine treatment in adulthood. Pregnant female Wistar rats were exposed to 12 commercially filtered cigarettes per day for a period of 28 days. We evaluated motor activity and cholinesterase activity in the brain and serum of adult male offspring that were administered acute subanesthetic doses of ketamine (5, 15 and 25 mg/kg), which serves as an animal model of schizophrenia. To determine locomotor activity, we used the open field test. Cholinesterase activity was assessed by hydrolysis monitored spectrophotometrically. Our results show that both PCSE and ketamine treatment in the adult offspring induced increase of locomotor activity. Additionally, it was observed increase of acetylcholinesterase and butyrylcholinesterase activity in the brain and serum, respectively. We demonstrated that animals exposed to cigarettes in the prenatal period had increased the risk for psychotic symptoms in adulthood. This also occurs in a dose-dependent manner. These changes provoke molecular events that are not completely understood and may result in abnormal behavioral responses found in neuropsychiatric disorders, such as schizophrenia.
Collapse
Affiliation(s)
- Alexandra I Zugno
- Laboratório de Neurociências, Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), and Núcleo de Excelência em Neurociências Aplicadas de Santa Catarina (NENASC), Programa de Pós-Graduação em Ciências da Saúde, Unidade Acadêmica de Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88806-000 Criciúma, SC, Brazil.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Ohmura Y, Tsutsui-Kimura I, Yoshioka M. Impulsive Behavior and Nicotinic Acetylcholine Receptors. J Pharmacol Sci 2012; 118:413-22. [DOI: 10.1254/jphs.11r06cr] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|